Aldevron Breakthrough Blog / Jeff Briganti

Looking back at 2022

Four events that made it a great year

I must admit, I’m a sucker for just about any list article. Show me a title such as, “8 Reasons Why…” or “10 Movies That…”, and there’s a pretty good chance I’ll click. I often find myself scrolling through the strangest lists, reviewing things that I really don’t care about – kitchen gadgets, closet organizing products, stocking stuffers. I’m hopeless. I’m compelled to click.

Read More

Webinar on Demand: Advanced Plasmid Technology – Improving Safety and Performance

Nanoplasmid™ Vectors: The Power of Small

In cell and gene therapies, delivery is a critical factor. Regardless of your modality, optimizing payload, impact, and duration are common challenges. Countless programs, globally, are working on the delivery mechanism. However, many have overlooked a key component in improving therapeutic or manufacturing performance: the plasmid.

Read More

100-Day Review – From Research to Clinic, and a Pet Project

Insider Insights Inspire Ideas

I’ve spent most of the last 30 years in marketing and sales for molecular biology research products. During that time, I’ve been responsible for software platforms and instrumentation, but my main focus has been on reagents and consumables – nucleic acid purification, PCR, cloning tools, and so forth.

Read More

A Complete Suite of rAAV Constructs

New ITR Cloning and Reporter Constructs Now Available
By Jeff Briganti, Senior Director, Global Strategic Marketing

Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category.

For recombinant adeno-associated virus (rAAV) viral vector production, we now offer several off-the-shelf ITR cloning backbones and GFP reporter constructs to complement our standardized set of OTS helper and packaging plasmids. This product set is available license and royalty free for research through commercial rAAV applications.

Utilizing this standardized portfolio can provide significant time and cost reduction, expediting time to market and de-risking specialized, transformative therapeutic development. By partnering with a contract development and manufacturing organization (CDMO) offering a complete suite of plasmids for viral vector production, researchers can streamline their upfront development while minimizing supply chain disruption throughout their program’s lifecycle.

For full information about our new product offering or to request a sample, visit our pALD-ITR Products page.

Read More